The global market for Advanced Therapy Medicinal Products was valued at US$13.0 Billion in 2024 and is projected to reach US$25.4 Billion by 2030, growing at a CAGR of 11.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The field of ATMPs has seen rapid advancements due to significant progress in biotechnology and a deeper understanding of genetic and cellular mechanisms. Innovations such as CRISPR-Cas9 gene editing, induced pluripotent stem cells (iPSCs), and advanced tissue scaffolding techniques have expanded the possibilities for developing effective and targeted therapies. The growing number of clinical trials and successful approvals of ATMPs by regulatory bodies such as the FDA and EMA highlight their therapeutic potential and market viability. Collaborations between academic institutions, biotech companies, and pharmaceutical giants are accelerating the development pipeline, bringing more ATMPs closer to commercialization. Additionally, advancements in manufacturing technologies and scalable production processes are making these therapies more accessible and cost-effective.
The growth in the ATMP market is driven by several factors. Firstly, the increasing prevalence of chronic and genetic diseases, which are often inadequately addressed by traditional treatments, is driving demand for innovative therapies like ATMPs. Secondly, significant advancements in biotechnology and genetic engineering are enabling the development of more effective and personalized ATMPs. Thirdly, substantial investments in research and development by biotech firms and pharmaceutical companies are accelerating the discovery and commercialization of new ATMPs. Additionally, the favorable regulatory environment and expedited approval pathways for breakthrough therapies are facilitating faster market entry for ATMPs. Lastly, the growing patient and physician awareness of the benefits of advanced therapies, coupled with the expanding infrastructure for ATMP manufacturing and distribution, are further propelling the market's growth.
Global Advanced Therapy Medicinal Products Market - Key Trends & Drivers Summarized
Advanced Therapy Medicinal Products (ATMPs) represent a frontier in medical innovation, encompassing gene therapies, cell therapies, and tissue-engineered products designed to treat, diagnose, or prevent diseases through advanced biological methods. ATMPs offer groundbreaking treatments for conditions that are currently difficult or impossible to treat with conventional medicines, including various cancers, genetic disorders, and degenerative diseases. These therapies work by modifying the genetic makeup of cells, harnessing the body's own repair mechanisms, or replacing damaged tissues, thus providing highly personalized and potentially curative treatments. The development and approval of ATMPs are subject to stringent regulatory processes, ensuring their safety, efficacy, and quality.The field of ATMPs has seen rapid advancements due to significant progress in biotechnology and a deeper understanding of genetic and cellular mechanisms. Innovations such as CRISPR-Cas9 gene editing, induced pluripotent stem cells (iPSCs), and advanced tissue scaffolding techniques have expanded the possibilities for developing effective and targeted therapies. The growing number of clinical trials and successful approvals of ATMPs by regulatory bodies such as the FDA and EMA highlight their therapeutic potential and market viability. Collaborations between academic institutions, biotech companies, and pharmaceutical giants are accelerating the development pipeline, bringing more ATMPs closer to commercialization. Additionally, advancements in manufacturing technologies and scalable production processes are making these therapies more accessible and cost-effective.
The growth in the ATMP market is driven by several factors. Firstly, the increasing prevalence of chronic and genetic diseases, which are often inadequately addressed by traditional treatments, is driving demand for innovative therapies like ATMPs. Secondly, significant advancements in biotechnology and genetic engineering are enabling the development of more effective and personalized ATMPs. Thirdly, substantial investments in research and development by biotech firms and pharmaceutical companies are accelerating the discovery and commercialization of new ATMPs. Additionally, the favorable regulatory environment and expedited approval pathways for breakthrough therapies are facilitating faster market entry for ATMPs. Lastly, the growing patient and physician awareness of the benefits of advanced therapies, coupled with the expanding infrastructure for ATMP manufacturing and distribution, are further propelling the market's growth.
Scope of the Study
The report analyzes the Advanced Therapy Medicinal Products market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments:
Type (Tissue Engineered Products, Cell Therapy, Gene Therapy, CAR-T Therapy).Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Tissue Engineered Products segment, which is expected to reach US$10.5 Billion by 2030 with a CAGR of a 12.5%. The Cell Therapy segment is also set to grow at 11.1% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $5.6 Billion in 2024, and China, forecasted to grow at an impressive 10.2% CAGR to reach $1.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Bluebird Bio Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., JCR Pharmaceuticals Co. Ltd. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Advanced Therapy Medicinal Products Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Advanced Therapy Medicinal Products Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Advanced Therapy Medicinal Products Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 190 major companies featured in this Advanced Therapy Medicinal Products market report include:
- Bluebird Bio Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- JCR Pharmaceuticals Co. Ltd.
- Kolon TissueGene, Inc.
- MEDIPOST Co., Ltd.
- Novartis AG
- Organogenesis Inc.
- Spark Therapeutics, Inc.
- UniQure N.V.
- Vericel Corporation
Table of Contents
I. METHODOLOGYMII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned
- Bluebird Bio Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- JCR Pharmaceuticals Co. Ltd.
- Kolon TissueGene, Inc.
- MEDIPOST Co., Ltd.
- Novartis AG
- Organogenesis Inc.
- Spark Therapeutics, Inc.
- UniQure N.V.
- Vericel Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 436 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 13 Billion |
| Forecasted Market Value ( USD | $ 25.4 Billion |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
